Drug intelligence / Profile preview

dasiglucagon + insulin aspart + insulin lispro

Development stage
Unknown
Lead developer
Zealand Pharma
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

This is a combination of three distinct medications used in diabetes management:\n\n**Dasiglucagon**: A glucagon analog used to treat severe hypoglycemia in pediatric and adult patients with diabetes. It consists of 29 amino acids similar to endogenous glucagon but contains seven substituted amino acids for improved physical and chemical stability. Dasiglucagon acts to increase blood sugar levels and is available as a subcutaneous injection marketed as Zegalogue.\n\n**Insulin Aspart**: A rapid-acting insulin analog used to improve glycemic control in patients with diabetes. It has a more rapid onset of action compared to regular insulin, allowing for administration right at mealtime and providing better glycemic control while avoiding hypoglycemic episodes from errors in timing.\n\n**Insulin Lispro**: A rapid-acting insulin analog used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. It begins to exert its effects within 15 minutes of subcutaneous administration, with peak levels occurring 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, it is considered \"bolus insulin\" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals.

02

Targets

GCGR (Glucagon receptor)INSR (Insulin receptor)

Beyond the preview

Go deeper on dasiglucagon + insulin aspart + insulin lispro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dasiglucagon + insulin aspart + insulin lispro.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call